Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

Meanwhile, if you buy the shares while they're down, you will have gotten in on the stock for a bargain -- and can maximize ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

Stay updated with real-time stock market news, Sensex & Nifty movements, top gainers and losers, expert analysis, IPO updates ...

In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...

In a recent market update, Goldman Sachs raised its year-end forecast for the S&P 500 (SPX) to 6,900 by year-end, up from a ...

Australian shares have rebounded impressively since April, but the real test will be the upcoming earnings season.

Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.

Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's ...